Neuroblastoma growth inhibition by Dichloroacetate


Recently substantial evidence from experiments in vitro as well as experiments in vivo models has shown that DCA can be useful in treating various types of cancer in humans. One of the most attractive qualities of DCA resides in its safety and tolerability which makes it a very desirable research subject in the field of cancer treatment.

For some time it was thought that DCA should most likely be ineffective against neuroblastoma, however, a recent study proved otherwise and its discoveries brought to light relatively unexpected results. To our surprise, dichloroacetate appears to have a positive effect on malignant NB tumor growth. The study has proven that DCA works against poorly differentiated neuroblastoma cells and is able to reduce NB tumor size and enlargement.

Firstly, the researchers discovered that DCA reduces cancer cell proliferation. At the end of the study it was proven that the DCA treatment on neuroblastoma cells works by inducing a close-dependent cell cycle delay. To put it in a nutshell, dichloroacetate can slow down NB tumor enlargement and possibly decrease the malignant potential of cancer. Furthermore, the study found out that even though the DCA treatment couldn't provide satisfying results on well differentiated and less aggressive NB cancer cells, DCA did prove to be effective against poorly differentiated and malignant neuroblastoma cells. Prior to the research it was believed that DCA had no action on NB cancer at all. Finally, the most appealing discovery was that DCA is effective on human neuroblastoma tumor cells.

The experimental 4 week treatment resulted in a significant NB tumor mass reduction. Surely, it is important to note that the effectiveness of the treatment appears to be related to the size of the dose.

2,5 mg/kg doses decreased the NB tumor size by 30%.
25 mg/kg doses shrunk the tumors by 55%.

All in all, the outcome appears to be great and makes it clear that DCA can be considered as a promising substance against cancer. The results of the study support the view of DCA as a very selective drug that is capable to help NB anticancer treatments without providing considerable adverse reactions.

If you would be delighted to find out more, please do so below:
Dichloroacetate inhibits neuroblastoma growth